A vaccine targeting multiple epitopes of the KRAS molecule in a mouse model of a KRAS-driven lung tumor elicited Th1 immune response and reduced tumor burden and tumor number by > 80% in a genetically engineered mouse model for KRAS driven lung adenocarcinoma [57]. This evidence concerns the gene KRAS and neoplasm.